Fulvestrant - AstraZeneca

Drug Profile

Fulvestrant - AstraZeneca

Alternative Names: Faslodex; ICI 182780; ZD 182780; ZD 9238; ZM 182780

Latest Information Update: 10 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Baylor Research Institute
  • Class Antineoplastics; Estradiol congeners; Estrenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Precocious puberty
  • No development reported Endometrial cancer
  • Discontinued Endometriosis

Most Recent Events

  • 25 Aug 2018 AstraZeneca terminates a phase III trial in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Inresectable, Recurrent) in Japan (NCT03430466) (UMIN000026050)
  • 01 Jun 2018 Efficacy and adverse events data from the phase III MONARCH-2 trial in Breast cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 12 Feb 2018 AstraZeneca settles lawsuits filed against Teva Pharmaceuticals and Fresenius Kabi related to ANDA submissions for fulvestrant in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top